



SAFETY DATA SHEET

Revision date: 03-Jan-2017

Version: 1.1

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Crisaborole Ointment

Trade Name: EUCRISA

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%

SAFETY DATA SHEET

Material Name: Crisaborole Ointment
Revision date: 03-Jan-2017

Page 2 of 9
Version: 1.1

3. COMPOSITION / INFORMATION ON INGREDIENTS

Crisaborole	906673-24-3	Not Listed	Not Listed	2
Butylated hydroxytoluene	128-37-0	204-881-4	Not Listed	*
Paraffin	8002-74-2	232-315-6	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Glycerides, C16-18 mono- and di-	85251-77-0	286-490-9	Not Listed	*
Edetate calcium disodium	62-33-9	200-529-9	Not Listed	*
White petrolatum	8009-03-8	232-373-2	Not Listed	*
Propylene glycol	57-55-6	200-338-0	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

SAFETY DATA SHEET

Material Name: Crisaborole Ointment
Revision date: 03-Jan-2017

Page 3 of 9
Version: 1.1

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

White petrolatum

ACGIH Threshold Limit Value (TWA) 5 mg/m³ (oil mist, mineral)
ACGIH Threshold Limit Value (STEL) 10 mg/m³ (oil mist, mineral)

Propylene glycol

Australia TWA 150 ppm
474 mg/m³
10 mg/m³
Ireland OEL - TWAs 150 ppm
470 mg/m³
10 mg/m³
Latvia OEL - TWA 7 mg/m³
Lithuania OEL - TWA 7 mg/m³

Butylated hydroxytoluene

ACGIH Threshold Limit Value (TWA) 2 mg/m³
Australia TWA 10 mg/m³
Austria OEL - MAKs 10 mg/m³
Belgium OEL - TWA 2 mg/m³
Bulgaria OEL - TWA 10 mg/m³
Denmark OEL - TWA 10 mg/m³
Finland OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³

SAFETY DATA SHEET

Material Name: Crisaborole Ointment
Revision date: 03-Jan-2017

Page 4 of 9
Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Germany - TRGS 900 - TWAs	10 mg/m ³
Germany (DFG) - MAK	10 mg/m ³ can occur as vapor and aerosol at the same time
Greece OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Portugal OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL -TWAs	10 mg/m ³

Paraffin

ACGIH Threshold Limit Value (TWA)	2 mg/m ³
Australia TWA	2 mg/m ³
Belgium OEL - TWA	2 mg/m ³
Denmark OEL - TWA	2 mg/m ³
Estonia OEL - TWA	2 mg/m ³
Finland OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Ireland OEL - TWAs	2 mg/m ³
Poland OEL - TWA	2 mg/m ³
Portugal OEL - TWA	2 mg/m ³
Romania OEL - TWA	2 mg/m ³
Spain OEL - TWA	2 mg/m ³
Switzerland OEL -TWAs	2 mg/m ³
Vietnam OEL - TWAs	1 mg/m ³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Crisaborole

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Hands:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

SAFETY DATA SHEET

Material Name: Crisaborole Ointment
Revision date: 03-Jan-2017

Page 5 of 9
Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Ointment	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Crisaborole

No data available

White petrolatum

No data available

Propylene glycol

No data available

Paraffin

No data available

Butylated hydroxytoluene

No data available

Edetate calcium disodium

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

SAFETY DATA SHEET

Material Name: Crisaborole Ointment
Revision date: 03-Jan-2017

Page 6 of 9
Version: 1.1

10. STABILITY AND REACTIVITY

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information in this section describes the potential hazards of the individual ingredients and the formulation.

Known Clinical Effects:

Adverse effects associated with therapeutic use include hypersensitivity reactions, itching sensation (pruritus), hives, redness and swelling of the skin (urticaria), and pain.

Acute Toxicity: (Species, Route, End Point, Dose)

Crisaborole

Rat Oral LD50 > 500 mg/kg

Propylene glycol

Rat Oral LD 50 22,000 mg/kg

Mouse Oral LD 50 24,900mg/kg

Rabbit Dermal LD 50 20,800mg/kg

Paraffin

Rat Oral LD50 >3750 mg/kg

Rabbit Dermal LD50 >3600mg/kg

Butylated hydroxytoluene

Rat Oral LD50 1700 mg/kg

Mouse Oral LD50 650 mg/kg

Rat Oral LD50 890 mg/kg

Mouse Intraperitoneal LD 50 138 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Crisaborole

Skin Irritation Rabbit Negative

Skin Sensitization - LLNA Mouse Negative

Propylene glycol

Skin Irritation Rabbit Mild

Eye Irritation Rabbit Mild

Paraffin

Skin Irritation Rabbit Mild

Eye Irritation Rabbit Mild

Butylated hydroxytoluene

Eye Irritation Rabbit Moderate

Skin Irritation Rabbit Moderate

SAFETY DATA SHEET

Material Name: Crisaborole Ointment
Revision date: 03-Jan-2017

Page 7 of 9
Version: 1.1

11. TOXICOLOGICAL INFORMATION

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Crisaborole

13 Week(s) Rat Oral 150 mg/kg/day NOEL Liver, Kidney, Female reproductive system
6 Month(s) Rat Oral 450 mg/kg/day NOAEL Blood

Butylated hydroxytoluene

4 Week(s) Rat Oral 5185 mg/kg LOAEL Liver
4 Day(s) Mouse Oral 2000 mg/kg LOAEL Liver, Kidney, Ureter, Bladder

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Crisaborole

Fertility and Embryonic Development Rat Oral 600 mg/kg/day NOAEL Negative
Embryo / Fetal Development Rat Oral 300 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rabbit Oral 100 mg/kg/day NOAEL Not Teratogenic
Peri-/Postnatal Development Rat Oral 300 mg/kg/day NOAEL Negative

Butylated hydroxytoluene

Embryo / Fetal Development Rat Oral 6 g/kg LOEL Teratogenic,

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Crisaborole

In Vitro Not specified Negative
In Vivo Not specified Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Crisaborole

2 Year(s) Rat Oral 300 mg/kg/day NOAEL Not carcinogenic
2 Year(s) Mouse Dermal 7 % NOAEL Not carcinogenic

Carcinogen Status:

Not listed as a carcinogen by IARC, NTP or US OSHA.

Butylated hydroxytoluene

IARC: Group 3 (Not Classifiable)

Product Level Toxicity Data

Irritation / Sensitization

Study Type	Species	Result
Skin Irritation	Rabbit	Slight
Eye Irritation	Rabbit	Slight

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated.

SAFETY DATA SHEET

Material Name: Crisaborole Ointment
Revision date: 03-Jan-2017

Page 8 of 9
Version: 1.1

Toxicity: No data available
Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Crisaborole

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Glycerides, C16-18 mono- and di-

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	286-490-9

Edetate calcium disodium

SAFETY DATA SHEET

Material Name: Crisaborole Ointment
Revision date: 03-Jan-2017

Page 9 of 9
Version: 1.1

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-529-9

White petrolatum

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 28.
REACH - Carcinogens Category 2:	Present
EU EINECS/ELINCS List	232-373-2

Propylene glycol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-338-0

Butylated hydroxytoluene

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-881-4

Paraffin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-315-6

16. OTHER INFORMATION

Data Sources:	Safety data sheets for individual ingredients. Pfizer proprietary drug development information.
Reasons for Revision:	Updated Section 11 - Toxicology Information. Updated Section 2 - Hazard Identification.
Revision date:	03-Jan-2017 Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet